Observational study evaluates visual improvements in refractory diabetic macular edema with faricimab, suggesting potential benefits.
Faricimab treatment led to modest early improvements in visual acuity and retinal anatomy overall in patients with refractory DME. The reduction in total IRF at Month 4 may be attributable to Ang-2 inhibition in these patients, who had previously not responded to anti-VEGF treatment alone. Longer-term studies are needed to evaluate the durability and long-term efficacy of faricimab for the treatment of refractory DME.
No takes yet. Share an insight, caveat, or question.
Owlya et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: